Antiphospholipid Syndrome: primary or secondary to Systemic Lupus Erythematosus? Description of a clinical case of avitaminosis D in premenopausal woman with pseudo-Cushing syndrome

Mauro Turrin, Sergio Martinelli

DOI: https://doi.org/10.7175/cmi.v8i2.912

Abstract

Low vitamin D levels have been described in obese individuals and in some autoimmune diseases, such as Systemic Lupus Erythematosus (SLE) and primary antiphospholipid syndrome (pAPS). In particular, more than 50% of premenopausal women with pAPS have hypovitaminosis D. In this issue we report a case of an obese, premenopausal, and hypertensive woman with pseudo-Cushing syndrome, affected by deep venous thrombosis associated with pulmonary embolism after rib fracture who presented hypovitaminosis D. 7 years before, diagnosis of pAPS had been made after the detection of thrombocytopenia (present at a young age) and arterial ischemia of a lower limb. For seven years she was treated with acetylsalicylic acid without complications. We found positive anti-dsDNA antibodies, a triple antiphospholipid antibodies (aPL) positivity and levels of vitamin D < 4 µg/l. The case report arises some questions: is vitamin D deficiency due to obesity or APS? Is the positivity of anti-dsDNA indicative of progression to SLE? Is preventive therapy with hydroxychloroquine indicated? Does the high-risk aPL profile justify a high-intensity and life-long anticoagulation regimen?

Keywords

Antiphospholipid syndrome; Venous thromboembolism; Thrombocytopenia; Oral anticoagulation; Vitamin D; Systemic Lupus Erythematosus; Obesity; Autoantibodies; Autoimmunity

Full Text

HTML PDF

References

  • Amital H, Szekanecz Z, Szucs G, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis 2010; 69: 1155-7; http://dx.doi.org/10.1136/ard.2009.120329
  • Mok CC, Birmingham DJ, Leung HW, et al. Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis. Rheumatology 2012; 51: 644-52; http://dx.doi.org/10.1093/rheumatology/ker212
  • Ritterhouse LL, Crowe SR, Niewold TB, et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis 2011; 70: 1569-74; http://dx.doi.org/10.1136/ard.2010.148494
  • Klack K, Carvalho JF. High frequency of vitamin D insufficiency in primary antiphospholipid syndrome. Joint Bone Spine 2010; 77: 489-90; http://dx.doi.org/10.1016/j.jbspin.2010.02.043
  • Piantoni S, Andreoli L, Allegri F, et al. Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. Reumatismo 2012; 64: 307-13; http://dx.doi.org/10.4081/reumatismo.2012.307
  • Paupitz JA, Freire de Carvalho J, Caparbo VF, et al. Primary antiphospholipid syndrome in premenopausal women: low vitamin D, hight fat mass and maintained bone mineral mass. Lupus 2010; 19: 1302-6; http://dx.doi.org/10.1177/0961203310372938
  • Andreoli L, Piantoni S, Dall’Ara F, et al. Vitamin D and antiphospholipid syndrome. Lupus 2012; 21: 736-40; http://dx.doi.org/10.1177/0961203312446386
  • Agmon-Levin N, Blank M, Zandman-Goddard G, et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis 2011; 70: 145-50; http://dx.doi.org/10.1136/ard.2010.134817
  • Adami S, Romagnoli E, Carnevale V, et al. Linee guida su prevenzione e trattamento dell’ipovitaminosi D con colecalciferolo Reumatismo 2011; 63: 129-47
  • Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72: 690-3
  • Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46; 1019-27; http://dx.doi.org/10.1002/art.10187
  • Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306; http://dx.doi.org/10.1111/j.1538-7836.2006.01753.x
  • Ramos-Casals M, Campoamor MT, Chamorro A, et al. Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus 2004; 13: 777-83; http://dx.doi.org/10.1191/0961203304lu1080oa
  • Gòmez-Puerta JA, Martìn H, Amigo MC, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine 2005; 84: 225-30; http://dx.doi.org/10.1097/01.md.0000172074.53583.ea
  • Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010; 62: 863-8; http://dx.doi.org/10.1002/art.27289
  • Costedoat-Chalumeau N, Leroux G, Piette JC, et al. Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment? Joint Bone Spine 2010; 77: 4-5; http://dx.doi.org/10.1016/j.jbspin.2009.09.007
  • Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20-8; http://dx.doi.org/10.1136/ard.2008.101766
  • Akhavan PS, Su J, Lou W, et al. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol 2013; 40: 831-41; http://dx.doi.org/10.3899/jrheum.120572
  • Broder A, Putterman C. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol 2013; 40: 30-3; http://dx.doi.org/10.3899/jrheum.120157
  • Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-β2-glycoprotein I complexes to phospholipid bilayers. Blood 2008; 112: 1687-95; http://dx.doi.org/10.1182/blood-2008-03-144204
  • Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarian drug. Blood 2010; 115: 2292-9; http://dx.doi.org/10.1182/blood-2009-04-213520
  • Ruiz-Irastorza G, Cuadraro MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20: 206-18; http://dx.doi.org/10.1177/0961203310395803
  • Pengo V, Denas G, Banzato A, et al. Secondary prevention in thrombotic antiphospholipid syndrome. Lupus 2012; 21: 734-5; http://dx.doi.org/10.1177/0961203312444773
  • Crowter MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8; http://dx.doi.org/10.1056/NEJMoa035241
  • Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-53; http://dx.doi.org/10.1111/j.1538-7836.2005.01340.x
  • Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237-42; http://dx.doi.org/10.1111/j.1538-7836.2009.03674.x
  • Cikrikcioglu MA, Hursitoglu M, Erkal H, et al. Splenomegaly in primary antiphospholipid syndrome without accompanying portal hypertension or comorbidity. Pathophysiol Haemost Thromb 2010; 37: 104-9

Statistics

Abstract: 1031 views
HTML: 2383 views
PDF: 10412 views

Refbacks

  • There are currently no refbacks.